



June 21, 2011

To whom it may concern

Company name: Fuji Pharma Co., Ltd.
Representative: Hirofumi Imai, President & CEO
(Securities Code: 4554)
Contact: Toyoyuki Kamide
Director and General Manager
Administration Department
+81-(0)3-3556-3344

Listing of Fuji Pharma Co., Ltd., on the Second Section of the Tokyo Stock Exchange

We hereby announce that Fuji Pharma Co., Ltd. (the “Company”), as of today, received approval from the Tokyo Stock Exchange, Inc. for its listing on the Second Section of the Tokyo Stock Exchange.

The scheduled listing will take place on July 11, 2011 (Monday). From that date forward, the Company’s stock will be on offer to be bought and sold both on the Tokyo Stock Exchange and the Osaka Securities Exchange (JASDAQ).

The Company has achieved this milestone thanks to your support and cooperation and that of shareholders and other stakeholders.

We intend to continue to further expand our businesses and improve our corporate value. Your ongoing engagement is highly appreciated.

For details of our listing on the Second Section of the Tokyo Stock Exchange, please refer to the Web site of the exchange (<http://www.tse.or.jp/>).